Subtopic Deep Dive
Lymphatic Malformations Sirolimus Therapy
Research Guide
What is Lymphatic Malformations Sirolimus Therapy?
Lymphatic Malformations Sirolimus Therapy uses the mTOR inhibitor sirolimus to treat macrocystic and microcystic lymphatic anomalies unresponsive to sclerotherapy by reducing lesion volume and complications.
Sirolimus targets the PI3K/AKT/mTOR pathway implicated in vascular malformations. Clinical studies report efficacy in extensive slow-flow lesions with prospective phase II trials showing volume reduction. Over 200 papers cite key works like Dore et al. (2016, 217 citations) and Hammer et al. (2018, 212 citations).
Why It Matters
Sirolimus provides systemic control for inoperable lymphatic malformations, reducing chylous ascites and improving quality of life in pediatric patients (Hammer et al., 2018; Wiegand et al., 2018). It enables combination regimens with sclerotherapy for complex cases, lowering complication rates (Dore et al., 2016). Genetic insights into PIK3CA and NRAS mutations guide patient selection for targeted therapy (Queisser et al., 2021; Barclay et al., 2018).
Key Research Challenges
Long-term adverse events
Sirolimus therapy requires monitoring for immunosuppression and metabolic effects over years. Wiegand et al. (2018) systematic review calls for randomized trials to quantify risks. Pediatric growth impacts remain understudied (Dore et al., 2016).
Optimal dosing regimens
Varied dosing in monocentric studies leads to inconsistent volumetrics. Hammer et al. (2018) phase II trial used fixed schedules but lacked standardization. Combination with sclerotherapy needs protocol optimization (Seront et al., 2018).
Genetic patient stratification
Somatic mutations like PIK3CA and NRAS identify responders but testing is inconsistent. Queisser et al. (2021) highlight pathway variants; Barclay et al. (2018) report NRAS in kaposiform cases. Broad screening protocols are absent.
Essential Papers
Sirolimus in the Treatment of Vascular Anomalies
Mariela Dore, V Núñez Cerezo, Manuel Cervantes et al. · 2016 · European Journal of Pediatric Surgery · 217 citations
<b>Aim of the Study</b> mTOR inhibitors are showing promising results in the management of vascular anomalies. Although current controlled trials remain to be completed, many individual experiences...
Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study
Jennifer Hammer, Emmanuel Seront, Steven Duez et al. · 2018 · Orphanet Journal of Rare Diseases · 212 citations
Genetic Basis and Therapies for Vascular Anomalies
Angela Queisser, Emmanuel Seront, Laurence M. Boon et al. · 2021 · Circulation Research · 206 citations
Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositid...
Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies
Taija Mäkinen, Laurence M. Boon, Miikka Vikkula et al. · 2021 · Circulation Research · 205 citations
Lymphatic vessels maintain tissue fluid homeostasis by returning to blood circulation interstitial fluid that has extravasated from the blood capillaries. They provide a trafficking route for cells...
Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review
Susanne Wiegand, Gunnar Wichmann, Andreas Dietz · 2018 · Lymphatic Research and Biology · 166 citations
Available literature indicated that sirolimus therapy might be effective for lymphatic malformations. However, further randomized controlled studies are required to analyze the efficacy and long-te...
Chylous Ascites: Evaluation and Management
Said A. Al‐Busafi, Peter Ghali, Marc Deschênes et al. · 2014 · ISRN Hepatology · 166 citations
Chylous ascites refers to the accumulation of lipid-rich lymph in the peritoneal cavity due to disruption of the lymphatic system secondary to traumatic injury or obstruction. Worldwide, abdominal ...
Kaposiform hemangioendothelioma: current knowledge and future perspectives
Yi Ji, Siyuan Chen, Kaiying Yang et al. · 2020 · Orphanet Journal of Rare Diseases · 163 citations
Reading Guide
Foundational Papers
Start with Dore et al. (2016) for clinical series and Hammer et al. (2018) phase II trial to grasp efficacy basics; Al-Busafi et al. (2014) for chylous ascites context in lymphatic disruptions.
Recent Advances
Study Queisser et al. (2021) and Mäkinen et al. (2021) for genetic mechanisms; Van Damme et al. (2020) for emerging therapies including sirolimus combinations.
Core Methods
Volumetric MRI assessment, mTOR inhibition via sirolimus (1-5 mg/m²/day), PI3K/AKT pathway targeting; phase II monocentric trials and systematic reviews (Hammer et al., 2018; Wiegand et al., 2018).
How PapersFlow Helps You Research Lymphatic Malformations Sirolimus Therapy
Discover & Search
Research Agent uses searchPapers and exaSearch to find sirolimus trials for lymphatic malformations, revealing Dore et al. (2016) as top-cited. citationGraph maps mTOR pathway links from Queisser et al. (2021) to 200+ related works. findSimilarPapers expands from Hammer et al. (2018) phase II study.
Analyze & Verify
Analysis Agent applies readPaperContent to extract volumetrics from Hammer et al. (2018), then runPythonAnalysis with pandas to compute meta-analysis of complication rates across 10 studies. verifyResponse (CoVe) and GRADE grading verify efficacy claims against Wiegand et al. (2018) review, flagging low-evidence dosing data.
Synthesize & Write
Synthesis Agent detects gaps in long-term data via contradiction flagging between Dore et al. (2016) and recent genetics papers. Writing Agent uses latexEditText, latexSyncCitations for trial protocols, and latexCompile to generate review manuscripts with exportMermaid for PI3K/mTOR pathway diagrams.
Use Cases
"Compare sirolimus volume reduction rates in microcystic vs macrocystic lymphatic malformations from phase II trials."
Research Agent → searchPapers + findSimilarPapers → Analysis Agent → readPaperContent (Hammer 2018, Dore 2016) → runPythonAnalysis (pandas meta-analysis of volumetrics) → CSV export of stats table.
"Draft LaTeX review on sirolimus for PIK3CA-mutated vascular anomalies."
Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure (mTOR diagram) → latexSyncCitations (Queisser 2021 et al.) → latexCompile → PDF output with bibliography.
"Find GitHub repos analyzing sirolimus dosimetry from vascular malformation papers."
Research Agent → paperExtractUrls (Wiegand 2018) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis sandbox verification of dosing scripts.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ sirolimus papers: searchPapers → citationGraph → GRADE grading → structured report on efficacy. DeepScan applies 7-step analysis to Hammer et al. (2018) with CoVe checkpoints for volumetrics. Theorizer generates hypotheses on NRAS-targeted combos from Barclay et al. (2018) literature.
Frequently Asked Questions
What defines Lymphatic Malformations Sirolimus Therapy?
It employs mTOR inhibitor sirolimus for macrocystic/microcystic lymphatic anomalies unresponsive to sclerotherapy, targeting PI3K/AKT/mTOR pathway (Queisser et al., 2021).
What methods assess sirolimus efficacy?
Prospective phase II trials measure volumetrics and complications; systematic reviews aggregate outcomes (Hammer et al., 2018; Wiegand et al., 2018).
What are key papers?
Dore et al. (2016, 217 citations) reports pediatric series; Hammer et al. (2018, 212 citations) phase II study; Wiegand et al. (2018, 166 citations) systematic review.
What open problems exist?
Long-term safety, dosing standardization, and genetic stratification need RCTs; inconsistent mutation testing limits responders (Queisser et al., 2021; Barclay et al., 2018).
Research Vascular Malformations and Hemangiomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lymphatic Malformations Sirolimus Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers